Date: 2011-04-14
Type of information:
phase: 2
Announcement: finalization
Company: Novagali Pharma (France)
Product: Catioprost®
Action mechanism: Catioprost® is a preservative-free cationic emulsion containing 0.005% latanoprost, formulated to reduce intraocular pressure while simultaneously treating damage to the ocular surface. It combines latanoprost with Novagali Pharma's patented Novasorb® technology which has been shown to improve ocular surface damage in patients with dry eye disease.
Disease: glaucoma
Therapeutic area: Ophtalmological diseases
Country: USA
Trial details: The randomized phase II trial is a safety and efficacy study of Catioprost® compared to Travatan Z® to treat glaucoma and ocular surface disease. It has enrolled 105 patients in the United States.
Latest
news: Novagali Pharma has completed the enrolment for its phase II clinical trial of Catioprost® in patients with glaucoma and presenting concomitant damage to the ocular surface.
The Phase II clinical study follows preclinical studies at Mount Sinai Hospital in New York and Quinze-Vingts Hospital in Paris. These studies have shown the efficacy of Catioprost® in controlling intraocular pressure, the superiority of its safety profile3 and its potential for limiting and reversing damage to the ocular surface relative to other prostaglandin therapies for glaucoma.
